We are live on ! Find out more
TG

TLP Group Portfolio holdings

AUM $6.61M
1-Year Est. Return 12.46%
This Fund
S&P 500
This Quarter Est. Return
+18.07%
1 Year Est. Return
-12.46%
3 Year Est. Return
+42.65%
5 Year Est. Return
10 Year Est. Return
AUM
$144M
AUM Growth
-$14.9M
Cap. Flow
-$292K
Cap. Flow %
-0.2%
Top 10 Hldgs %
64.22%
Holding
794
New
229
Increased
159
Reduced
207
Closed
182

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$3.53M
2
PFE icon
Pfizer
PFE
+$2.63M
3
MRK icon
Merck
MRK
+$1.44M
4
AMGN icon
Amgen
AMGN
+$1.26M
5
LLY icon
Eli Lilly
LLY
+$976K

Sector Composition

Rank Sector Weight
1 Healthcare 8.73%
2 Financials 6.69%
3 Consumer Discretionary 5.75%
4 Industrials 4.37%
5 Technology 3.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$39.7M 27.53%
1,050,000
-934,476
-47% -$30.2M
SPY icon
2
State Street SPDR S&P 500 ETF Trust
SPY
$775B
$27.4M 19.02%
102,825
-11,383
-10% -$2.96M
XLV icon
3
State Street Health Care Select Sector SPDR ETF
XLV
$41.7B
$6.99M 4.85%
84,579
+10,308
+14% +$850K
IWM icon
4
iShares Russell 2000 ETF
IWM
$80.9B
$5.37M 3.72%
35,226
+23,511
+201% +$3.53M
PFE icon
5
Pfizer
PFE
$143B
$3.79M 2.63%
110,440
+77,028
+231% +$2.63M
SPY icon
6
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
$3.04M 2.11%
791,200
+34,500
+5% +$8.97M
MRK icon
7
Merck
MRK
$323B
$2.33M 1.62%
43,440
+25,958
+148% +$1.44M
XLF icon
8
State Street Financial Select Sector SPDR ETF
XLF
$54.9B
$1.57M 1.09%
56,340
-7,994
-12% -$215K
AMGN icon
9
Amgen
AMGN
$199B
$1.41M 0.97%
8,084
+7,124
+742% +$1.26M
LLY icon
10
Eli Lilly
LLY
$1.06T
$972K 0.67%
11,507
+11,466
+27,966% +$976K
QQQ icon
11
Invesco QQQ Trust
QQQ
$458B
$849K 0.59%
5,450
-655
-11% -$100K
XLV icon
12
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.7B
$702K 0.49%
757,700
+65,900
+10% +$5.43M
EQR icon
13
Equity Residential
EQR
$25.7B
$693K 0.48%
10,872
-4,355
-29% -$291K
OEF icon
14
PUT
iShares S&P 100 ETF
OEF
$19.8B
$638K 0.44%
173,300
+55,800
+47% +$6.44M
HIG icon
15
Hartford Financial Services
HIG
$39.1B
$614K 0.43%
10,908
+2,336
+27% +$130K
CELG
16
DELISTED
Celgene Corp
CELG
$611K 0.42%
5,850
+2,683
+85% +$303K
ALL icon
17
Allstate
ALL
$65.6B
$568K 0.39%
5,426
-874
-14% -$86.1K
VNO icon
18
Vornado Realty Trust
VNO
$7.33B
$560K 0.39%
7,169
+4,420
+161% +$338K
MS icon
19
Morgan Stanley
MS
$337B
$547K 0.38%
10,431
+2,031
+24% +$103K
F icon
20
Ford
F
$56.2B
$541K 0.38%
43,321
+6,265
+17% +$77.1K
URI icon
21
United Rentals
URI
$72.6B
$541K 0.38%
3,147
+134
+4% +$20.4K
IBB icon
22
iShares Biotechnology ETF
IBB
$9.33B
$512K 0.36%
+4,800
New +$513K
UAA icon
23
Under Armour
UAA
$2.91B
$487K 0.34%
33,771
+15,535
+85% +$224K
JPM icon
24
JPMorgan Chase
JPM
$925B
$441K 0.31%
4,125
-1,299
-24% -$132K
SM icon
25
SM Energy
SM
$8.07B
$437K 0.3%
+19,787
New +$399K

Similar funds

TLP Group's Q4 2017 Portfolio in Review

As of Q4 2017, TLP Group held 794 positions worth $144M, down 9.4% from $159M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

TLP Group's Q4 2017 filing shows 229 new, 159 increased, 207 reduced and 182 closed positions. Its largest new stake was iShares Biotechnology ETF: 4,800 shares worth $512K. The largest sale was Aimmune Therapeutics, an estimated $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 8.7% of assets, up from 4.8% a quarter earlier, followed by Financials and Consumer Discretionary.

  • TLP Group's largest Q4 2017 buy was iShares Biotechnology ETF: 4,800 shares worth $512K.
  • TLP Group added most to iShares Russell 2000 ETF in Q4 2017, an estimated $3.53M increase.
  • TLP Group's biggest Q4 2017 reduction was Aimmune Therapeutics, cutting an estimated $30.2M.
  • TLP Group fully exited Daseke, Inc. Warrant in Q4 2017, selling an estimated $417K.
  • TLP Group's ten largest holdings make up 64% of its $144M portfolio in Q4 2017.
  • TLP Group opened 229 new positions and closed 182 in Q4 2017.
  • TLP Group's portfolio value fell 9.4% quarter-over-quarter to $144M.

Based on TLP Group's 13F filing for Q4 2017, filed 14 Feb 2018.